Earlier this week, the Clinical Trials Fund was officially launched, supported by a Budget 2021 investment of $250 million over three years for the Canadian Institutes of Health Research. This launch reinforces and strengthens the clinical trials ecosystem in Canada, and will help support the training of new clinical researchers. Additionally, a new Northern Centre for Clinical Research in collaboration with the UBC Faculty of Medicine, the University of Northern British Columbia and Northern Health, is being launched to create more opportunities for clinical and biomedical research, and to improve care, in Northern BC.
As one of our province’s fastest growing sectors, life sciences plays a crucial role in driving growth not only for our provincial economy and health care system, but also nationally and globally. This is why we are so pleased to see organizations like Michael Smith Health Research BC behind resources like REACH BC to help propel health research and outcomes forward. This publicly funded online platform connects researchers and academics with members of the public/ patients who want to take part in the numerous studies taking place across the province. We encourage you to learn more about this fantastic resource today!
We also want to highlight an exciting opportunity from the National Research Council of Canada, who put out a call for a co-founder to jointly establish a not-for-profit corporation to govern the Biologics Manufacturing Centre. This is a great chance for an organization with the right entrepreneurial drive to operate a brand new, end-to-end biomanufacturing facility, and to help shape the future of this important asset for Canada. A virtual information session will be held on July 6th, and applications will be accepted until August 1st.
Big news from Pfizer Canada and BioNTech who have filed a Supplemental New Drug Submission with Health Canada for use of COMIRNATY, a vaccine to help prevent COVID-19 in children six months to under five years of age. Also, Bold Therapeutics announced that its BOLD-100 early mCRC data would be showcased at 2022 Metals in Medicine Gordon Research Conference.
People on the Move
We’d like to congratulate some people who have started in new roles: Zymeworks appointed Dr. Paul Moore as their Chief Scientific Officer and Jacek Mis joined HTuO Biosciences as their Director of Business Development.
Awards
There are so many exciting developments and innovations happening within our sector each and every week. At LSBC, it is truly our privilege to help support, promote, and represent this amazing community across the province.
Wishing everyone a safe and happy long weekend!
Until next week,
Wendy and the LSBC team
|
|
|
|
UBC’s Academy of Translational Medicine and UBC Extended Learning Offer a New Micro-Certificate in Regulatory Affairs in the Life Sciences
With financial support from the BC Ministry of Advanced Education and Skills Training, the UBC Academy of Translational Medicine has partnered with UBC Extended Learning to offer the UBC Micro-certificate in Regulatory Affairs for the Life Sciences. This program consists of two five-week part-time courses, which will run back-to-back September to November 2022, that can be taken separately or stacked into a UBC Micro-certificate... READ MORE
|
|
|
|
Cancer Drug Shows Potential as Treatment for Muscular Dystrophy
Researchers at UBC’s School of Biomedical Engineering have discovered that an existing cancer drug could have potential as a treatment for muscular dystrophy. The researchers found that the drug — known as a colony-stimulating factor 1 receptor (CSF1R) inhibitor — helped slow the progress of Duchenne muscular dystrophy in mice by increasing the resiliency of muscle fibres... READ MORE
|
|
|
|
Call for Co-Founder to Create a Not-For-Profit for the Biologics Manufacturing Centre
The National Research Council of Canada is seeking a co-founder to jointly establish, with the NRC, a not-for-profit corporation to govern the Biologics Manufacturing Centre. Under the governance of this new not-for-profit corporation, the Biologics Manufacturing Center will have the agility to operate with the efficiency of the private sector, while focusing on fulfilling a public good mandate which includes maximizing pandemic preparedness... READ MORE
|
|
|
|
New Research Centre to Foster Northern Clinical and Medical Life Sciences Research
The National Research Council of Canada is seeking a co-founder to jointly establish, with the NRC, a not-for-profit corporation to govern the Biologics Manufacturing Centre. Under the governance of this new not-for-profit corporation, the Biologics Manufacturing Center will have the agility to operate with the efficiency of the private sector, while focusing on fulfilling a public good mandate which includes maximizing pandemic preparedness... READ MORE
|
|
|
|
New Genome BC Project Uses Remote Sensing Technologies to Identify Trees Resistant to Climate Extremes
Increasingly severe heat and drought are weakening the health of BC’s forests. The growing season for trees is expanding, increasing exposure to frost as well as drought. This change results in significant damage, causing plantation reforestation to fail and decreasing the value of the harvested timber. One solution is to plant more resilient trees, however, identifying which tree species are resilient enough is a challenge... READ MORE
|
|
|
|
CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
AbbVie announced the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs... READ MORE
|
|
|
|
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Takeda and Arrowhead Pharmaceuticals Inc. announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency were recently published in the New England Journal of Medicine and presented in an oral presentation at The International Liver Congress™ 2022... READ MORE
|
|
|
|
UBC Researchers Launch New Dementia Prevention Program as Part of National Research Initiative
Researchers at UBC’s Faculty of Medicine are part of a national initiative launching a new dementia prevention program aimed at helping people reduce their risk of developing dementia. The Canadian Consortium on Neurodegeneration in Aging, Canada’s largest dementia research initiative, has launched Brain Health PRO — an innovative online program that offers older adults the opportunity to increase their knowledge of dementia, improve lifestyle risk factors and engage with researchers... READ MORE
|
|
|
|
Bold Therapeutics’ BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference
Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 from the 2022 ASCO General Meeting in metastatic colorectal cancer, one of the most difficult-to-treat solid tumour indications. If this data can be replicated in a larger sample size, it would dramatically improve outcomes for these patients... READ MORE
|
|
|
|
B.C.-Led Lawsuit Nets $150M Proposed Settlement with Purdue Pharma Over Opioid Harms
A proposed $150-million settlement with Purdue Pharma Canada covering all provinces and territories has been reached for the recovery of health-care costs related to the sale and marketing of opioid-based pain medication. British Columbia Attorney General David Eby said Wednesday that it’s the largest settlement of a governmental health-care cost claim in Canadian history. ..READ MORE
|
|
|
|
Government of Canada Strengthens Canada’s Clinical Trials Environment
Canadian Institutes of Health Research– Clinical trials are essential scientific studies that evaluate the safety, effectiveness, and outcomes of health interventions such as vaccines and treatments used across Canada to protect Canadians from diseases. The Government of Canada is working to reinforce the clinical trials environment so that we can improve health outcomes for Canadians while ensuring Canada is well-positioned to respond to future pandemics and other health priorities. ..READ MORE
|
|
|
|
Life Sciences British Columbia and Acetech Announce Partnership
With a vision of supporting leadership within the life sciences, biotech, and tech sectors, Life Sciences British Columbia (LSBC) is proud to partner with Acetech, a not-for-profit organization for leaders of companies innovating with technology. Bringing together shared values of inclusivity, a focus on community, and peers supporting peers, the LSBC/Acetech partnership is a collaboration dedicated to nurturing economic development within the province through the support and advancement of leadership across these sectors. ..READ MORE
|
|
Senior Statistical Programmer
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks is seeking a highly-motivated professional who is looking to grow their career with our company.
|
|
Director, Preclinical Pharmacology
Abdera Therapeutics is looking for curious and committed individuals who are ready for the opportunity to transform the way people living with cancer can be treated. They are relentless in their focus to offer new hope to families facing devastating diagnoses. They are in search of team members who work collaboratively with a diverse group of colleagues, respectfully engaging one another while collectively and inclusively tackling any challenges we may face. They are building an exciting and fast paced company passionate about discovering and developing tomorrow’s most innovative cancer therapies.
|
|
Senior Principal Scientist, Clinical Development, Clinical Pharmacology
Xenon is seeking a Senior Principal Scientist, Clinical Development, Clinical Pharmacology to join their team. The Senior Principal Scientist will be a key member of Xenon’s Clinical Development department and highly collaborative Clinical Development team, with involvement in a diverse range of activities. As a key focus, the Senior Principal Scientist will manage the preparation and updating of comprehensive Clinical Pharmacology (PK) Plans for assigned products, lead the preparation of clinical synopses and author and/or review a variety of clinical trial and regulatory documents, and be a key contributor to the interpretation of clinical data supporting clinical pharmacology throughout development from first in human to marketing applications.
|
|
Sonus Microsystems Inc. is the creator of a special type of ultrasound transducer fabricated with polymer materials (polyCMUTs). PolyCMUTs are considered a platform technology with applications in different markets, including Healthcare, Non-Destructive Testing (NDT), and consumer electronics. Some of the advantages of their technology are improved image quality, lower manufacturing costs, low-energy consumption, mechanical flexibility, optical transparency, among others.
|
|
HealthQb discovers why your fatigue, anxiety or pain persists, and guides you to a balanced nervous system. They are a diverse team of entrepreneurs, innovators and scientists connected by their commitment to creating a chronic pain-free world.
|
|
|
|
Post a Job on the LSBC Website! |
LSBC Membership Discounts on Job Postings
|
|
|
|
|
|
|
